European Commission Grants Marketing Approval for Moderna’s mRESVIA

European Commission Grants Marketing Approval for Moderna’s mRESVIA

By, Admin 27 August 2024

European Commission grants marketing approval for Moderna’s respiratory syncytial virus vaccine, mRESVIA

Overview

Moderna, Inc. announced that the European Commission (EC) has granted marketing authorization for mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The marketing authorization follows the Positive Opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The authorization is valid in all 27 EU member states, as well as Iceland, Liechtenstein and Norway.

Words from the CEO: Moderna

  • The European Commission's approval of mRESVIA is an important milestone for public health and highlights Moderna's mRNA leadership. This approval marks the first time an mRNA vaccine has been approved for a disease beyond Covid-19 in Europe,"" said Stéphane Bancel, chief executive officer of Moderna. 
  • mRESVIA safeguards older adults against severe RSV outcomes and is uniquely offered in a pre-filled syringe to enhance ease of administration, which can reduce vaccine preparation time and administrative errors.""

About RSV

  • RSV is a highly contagious seasonal respiratory virus and a leading cause of lower respiratory tract infections and pneumonia. 
  • It causes a particularly high burden of disease in infants and older adults. 
  • In the European Union, RSV is estimated to cause approximately 160,000 hospital admissions in adults each year, with 92% of these admissions occurring in adults aged 65 and over.

Marketing Authorization for mRESVIA

  • The marketing authorization for mRESVIA is based on positive data from the phase 3 clinical trial ConquerRSV, a global study conducted in approximately 37,000 adults ages 60 years or older in 22 countries. 
  • The primary analysis with 3.7 months of median follow-up found a vaccine efficacy (VE) against RSV lower respiratory tract disease (LRTD) of 83.7% (95.88% CI 66.0%, 92.2%), with these results published in The New England Journal of Medicine. 
  • In a supplementary analysis with 8.6 months of median follow-up, mRNA-1345 maintained durable efficacy, with sustained VE of 63.3% (95% CI: 48.7%, 73.7%) against RSV-LRTD, including two or more symptoms. VE was 74.6% (95% CI, 50.7, 86.9) against RSV-LRTD with =2 symptoms, including shortness of breath, and VE was 63.0% (95% CI, 37.3%, 78.2%) against RSV LRTD including three or more symptoms. 
  • The stringent statistical criterion of the study, a lower bound on the 95% CI of >20%, continued to be met for both endpoints. 
  • The most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia.

US FDA Approval

  • In May 2024, the US Food and Drug Administration (FDA) approved mRESVIA (mRNA-1345) to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. 
  • The approval was granted under a breakthrough therapy designation and marked Moderna's second approved mRNA product. 
  • Moderna has filed for mRNA-1345 marketing authorization applications in multiple markets worldwide.

About mRESVIA

  • mRESVIA is an RSV vaccine that consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein. 
  • The F glycoprotein is expressed on the surface of the virus and is required for infection by helping the virus to enter host cells. 
  • The prefusion conformation of the F protein is a significant target of potent neutralizing antibodies and is highly conserved across both RSV-A and RSV-B subtypes. 
  • The vaccine uses the same lipid nanoparticles (LNPs) as the Moderna Covid-19 vaccines.

About Moderna

  • Moderna is a leader in the creation of the field of mRNA medicine. 
  • Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!